Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Factor concentrates for treatment of hemophilia: clarification [letter; comment]

D Menache, LF Barker

Blood (1990) 75 (3): 810.

https://doi.org/10.1182/blood.V75.3.810a.810a

Published: 1990

Journal Articles

Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group [see comments]

D Menache, JP O'Malley, JB Schorr, B Wagner, C Williams, BM Alving, JO Ballard, SH Goodnight, WE Hathaway, MB Hultin

Blood (1990) 75 (1): 33–39.

https://doi.org/10.1182/blood.V75.1.33.33

Published: 1990

Journal Articles

Coagulation Factor IX concentrate: method of preparation and assessment of potential in vivo thrombogenicity in animal models

D Menache, HE Behre, CL Orthner, H Nunez, HD Anderson, DC Triantaphyllopoulos, DP Kosow

Blood (1984) 64 (6): 1220–1227.

https://doi.org/10.1182/blood.V64.6.1220.1220

Published: 1984

Journal Articles

Electron microscopy of fibrin Paris I

MW Mosesson, G Feldmann, D Menache

Blood (1980) 56 (1): 80–83.

https://doi.org/10.1182/blood.V56.1.80.80

Published: 1980

Journal Articles

Studies of platelet fibrinogen from a subject with a congenital plasma fibrinogen abnormality (fibrinogen Paris I)

M Jandrot-Perrus, MW Mosesson, MH Denninger, D Menache

Blood (1979) 54 (5): 1109–1116.

https://doi.org/10.1182/blood.V54.5.1109.1109

Published: 1979

Journal Articles

Congenital deficiency of blood clotting factors II, VII, IX, and X

KS Chung, A Bezeaud, JC Goldsmith, CW McMillan, D Menache, HR Roberts

Blood (1979) 53 (4): 776–787.

https://doi.org/10.1182/blood.V53.4.776.776

Published: 1979

Journal Articles

Congenital Abnormality of the Prothrombin Molecule (Factor II) in Four Siblings: Prothrombin Barcelona

F. JOSSO, M.D., J. MONASTERIO DE SANCHEZ, M.D., J. M. LAVERGNE, M.D., D. MENACHE, M.D., J. P. S0ULIER, M.D.

Blood (1971) 38 (1): 9–16.

https://doi.org/10.1182/blood.V38.1.9.9

Published: 1971

NARROW

Factor concentrates for treatment of hemophilia: clarification [letter; comment]

Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group [see comments]

Coagulation Factor IX concentrate: method of preparation and assessment of potential in vivo thrombogenicity in animal models

Electron microscopy of fibrin Paris I

Studies of platelet fibrinogen from a subject with a congenital plasma fibrinogen abnormality (fibrinogen Paris I)

Congenital deficiency of blood clotting factors II, VII, IX, and X

Congenital Abnormality of the Prothrombin Molecule (Factor II) in Four Siblings: Prothrombin Barcelona

Email alerts

ASH Publications

American Society of Hematology

Factor concentrates for treatment of hemophilia: clarification [letter; comment]

Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group [see comments]

Coagulation Factor IX concentrate: method of preparation and assessment of potential in vivo thrombogenicity in animal models

Electron microscopy of fibrin Paris I

Studies of platelet fibrinogen from a subject with a congenital plasma fibrinogen abnormality (fibrinogen Paris I)

Congenital deficiency of blood clotting factors II, VII, IX, and X

Congenital Abnormality of the Prothrombin Molecule (Factor II) in Four Siblings: Prothrombin Barcelona

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only